Regulatory Approval Uncertainty: The company's success heavily depends on obtaining and maintaining regulatory approvals (e.g., FDA for CyPath® Lung) for its diagnostic products, which are complex, costly, and may not be granted.

Clinical Trial Risk: Failure to successfully design, conduct, or complete clinical trials for its diagnostic candidates could prevent or delay product commercialization, wasting significant resources.

Commercialization and Market Adoption Challenges: Even with regulatory approval, there is no guarantee that BIAF's products will achieve market acceptance, widespread adoption by healthcare providers, or adequate reimbursement from payers, limiting revenue generation.